Substrate/inhibitor properties of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) towards the sugar moiety of nucleosides, including O'-alkyl analogues
- PMID: 10478487
- DOI: 10.1080/07328319908044850
Substrate/inhibitor properties of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) towards the sugar moiety of nucleosides, including O'-alkyl analogues
Abstract
Nucleoside analogues with modified sugar moieties have been examined for their substrate/inhibitor specificities towards highly purified deoxycytidine kinase (dCK) and thymidine kinases (tetrameric high-affinity form of TK1, and TK2) from human leukemic spleen. In particular, the analogues included the mono- and di-O'-methyl derivatives of dC, dU and dA, syntheses of which are described. In general, purine nucleosides with modified sugar rings were feebler substrates than the corresponding cytosine analogues. Sugar-modified analogues of dU were also relatively poor substrates of TK1 and TK2, but were reasonably good inhibitors, with generally lower Ki values vs TK2 than TK1. An excellent discriminator between TK1 and TK2 was 3'-hexanoylamino-2',3'-dideoxythymidine, with a Ki of approximately 600 microM for TK1 and approximately 0.1 microM for TK2. 3'-OMe-dC was a superior inhibitor of dCK to its 5'-O-methyl congener, consistent with possible participation of the oxygen of the (3')-OH or (3')-OMe as proton acceptor in hydrogen bonding with the enzyme. Surprisingly alpha-dT was a good substrate of both TK1 and TK2, with Ki values of 120 and 30 microM for TK1 and TK2, respectively; and a 3'-branched alpha-L-deoxycytidine analogue proved to be as good a substrate as its alpha-D-counterpart. Several 5'-substituted analogues of dC were good non-substrate inhibitors of dCK and, to a lesser extent, of TK2. Finally, some ribonucleosides are substrates of the foregoing enzymes; in particular C is a good substrate of dCK, and 2'-OMe-C is an even better substrate than dC.
Similar articles
-
Substrate/inhibitor specificities of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2).Adv Exp Med Biol. 1998;431:623-7. doi: 10.1007/978-1-4615-5381-6_120. Adv Exp Med Biol. 1998. PMID: 9598140
-
Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs.Biochem Biophys Res Commun. 1991 Apr 30;176(2):586-92. doi: 10.1016/s0006-291x(05)80224-4. Biochem Biophys Res Commun. 1991. PMID: 2025274
-
Expression of human mitochondrial thymidine kinase in Escherichia coli: correlation between the enzymatic activity of pyrimidine nucleoside analogues and their inhibitory effect on bacterial growth.Biochem Pharmacol. 2000 Jun 15;59(12):1583-8. doi: 10.1016/s0006-2952(00)00285-9. Biochem Pharmacol. 2000. PMID: 10799656
-
Recent advances in thymidine kinase 2 (TK2) inhibitors and new perspectives for potential applications.Curr Pharm Des. 2012;18(20):2981-94. doi: 10.2174/138161212800672787. Curr Pharm Des. 2012. PMID: 22571666 Review.
-
Structure-activity relationships for phosphorylation of nucleoside analogs to monophosphates by nucleoside kinases.Acta Biochim Pol. 1996;43(1):143-60. Acta Biochim Pol. 1996. PMID: 8790720 Review.
Cited by
-
Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2.Biochem J. 2000 Oct 1;351(Pt 1):167-71. doi: 10.1042/0264-6021:3510167. Biochem J. 2000. PMID: 10998359 Free PMC article.
-
Structure, physiological role, and specific inhibitors of human thymidine kinase 2 (TK2): present and future.Med Res Rev. 2008 Sep;28(5):797-820. doi: 10.1002/med.20124. Med Res Rev. 2008. PMID: 18459168 Free PMC article. Review.
-
Re-Discovery of Pyrimidine Salvage as Target in Cancer Therapy.Cells. 2022 Feb 20;11(4):739. doi: 10.3390/cells11040739. Cells. 2022. PMID: 35203388 Free PMC article. Review.
-
Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer.Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):15-22. doi: 10.1007/s00259-004-1713-8. Eur J Nucl Med Mol Imaging. 2005. PMID: 15586282 Clinical Trial.
-
2'-fluoro-2'-deoxycytidine inhibits Borna disease virus replication and spread.Antimicrob Agents Chemother. 2004 Apr;48(4):1422-5. doi: 10.1128/AAC.48.4.1422-1425.2004. Antimicrob Agents Chemother. 2004. PMID: 15047559 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical